Suppr超能文献

肥胖相关高血压的神经机制与管理

Neural mechanisms and management of obesity-related hypertension.

作者信息

Esler Murray D, Eikelis Nina, Lambert Elisabeth, Straznicky Nora

机构信息

Baker IDI Heart and Diabetes Institute, PO Box 6492, St. Kilda Road Central, Melbourne, Victoria 8008, Australia.

出版信息

Curr Cardiol Rep. 2008 Nov;10(6):456-63. doi: 10.1007/s11886-008-0072-7.

Abstract

The sympathetic nervous system is activated in human obesity and in the analogous experimental obesity produced by overfeeding. The causes remain uncertain and may be multiple. The consequences include hypertension, probably attributable to activation of the sympathetic outflow to the kidneys, and, more disputed, insulin resistance. The pattern of sympathetic activation in normal-weight and obesity-related hypertension differs in terms of the firing characteristics of individual sympathetic fibers (increased rate of nerve firing in normal-weight hypertensives, increased number of active fibers firing at a normal rate in obesity-hypertension) and the sympathetic outflows involved. The underlying mechanisms and the adverse consequences of the two modes of sympathetic activation may differ. Should antihypertensive drug therapy in obesity-hypertension specifically target the existing neural pathophysiology? Such an approach can be advocated on theoretical grounds. Perhaps more important is the requirement that chosen antihypertensives do not cause weight gain or insulin resistance.

摘要

在人类肥胖以及由过度喂养导致的类似实验性肥胖中,交感神经系统会被激活。其原因尚不确定,可能是多方面的。后果包括高血压,这可能归因于交感神经向肾脏的输出激活,而更具争议的是胰岛素抵抗。正常体重和肥胖相关高血压患者的交感神经激活模式在单个交感神经纤维的放电特征(正常体重高血压患者神经放电速率增加,肥胖高血压患者以正常速率放电的活跃纤维数量增加)以及涉及的交感神经输出方面有所不同。两种交感神经激活模式的潜在机制和不良后果可能不同。肥胖高血压的抗高血压药物治疗是否应专门针对现有的神经病理生理学?从理论角度可以提倡这种方法。或许更重要的是,所选的抗高血压药物不应导致体重增加或胰岛素抵抗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验